MRK · News · 20260807N

Geographic Market Commentary

Merck & Co., Inc. · 2026-08-07 · Importance 23 · Surprise 42

Merck’s Ervebo Ebola vaccine is being deployed more broadly in response to a worsening outbreak in eastern Democratic Republic of Congo. The outbreak involves the Bundibugyo strain and has produced nearly 4,000 cases and more than 1,800 deaths over 12 weeks. Observational evidence from Congo and Uganda is supporting expanded use despite the lack of formal proof of efficacy against this strain.

Key facts

• Assenagon Asset Management S.A. increased its Merck stake by 263.7% in Q2, now owning 2,702,992 shares valued at $347.33 million. source
• Merck EVP Guindo Chirfi sold 15,000 shares on August 6, 2026 at $131.00 per share, totaling approximately $1.97 million, leaving him with 46,613 shares. source
• Merck EVP David Michael Williams sold 52,847 shares for approximately $6.81 million, significantly reducing his direct ownership. source
• Czech National Bank acquired 27,039 additional Merck shares in Q2, increasing its stake by 4.0% to hold a total of 703,007 shares valued at $90,336,000. source
• PensionDanmark Pensionsforsikringsaktieselskab bought 54,260 Merck shares in Q2, increasing its stake by 13.3% to a total of 462,927 shares valued at $59.49 million. source
• Institutional investors collectively own 76.07% of Merck's stock. source